ACROMEGALY ARTHROPATHY: IS THERE SOMETHING MORE BEHIND THE PAIN? A CROSS-SECTIONAL STUDY TO EVALUATE RHEUMATIC DISEASE IN GROWTH HORMONE SECRETING TUMOR PATIENTS

M. Scarati1, S. Parici1, N. Prncipe2, M. C. Ditto2, E. Ghigo2, E. Fusaro2, S. Grotti2,1
1 Maurizio Hospital, Medical Department, Turin, Italy; 2 AOU Città della Salute e della Scienza, Turin, Italy

Background: Acromegaly is a rare disease with a remarkable impact on patients, both in terms of life expectancy and quality of life. Osteo-articular complications are one of the most frequently reported bothers. The “acromegaly arthropathy” characterizes more than 70% of patients at diagnosis. Arthropathy affects both spine and peripheral joints. A recent prospective study documented progression of acromegalic arthropathy identified as a worsening of osteophytes and joint space narrowing in 72–74% of patients despite long-term biochemical control. In addiction the Literature has occasionally reported cases of simultaneous presence of rheumatic diseases (rheumatoid arthritis, polyalgia rheumatica, undifferentiated connective tissue diseases) and acromegaly and in all these cases the treatment has been delayed, because of wrong symptoms attribution to acromegaly arthropathy.

Objectives: The primary goal of the study is to better characterize joint pain in acromegaly patients and to evaluate the prevalence of rheumatic disease in growth hormone (GH) secreting pituitary tumor patients.

Methods: We enrolled 20 acromegaly subjects (AS) and 20 control subjects (CS). In each subject immunological pattern (rheumatoid factor – RF; antinuclear antibodies - ANA, ENA; anti-citrullinated protein antibodies - ACPA; erythrocyte sedimentation rate – ESR) has been evaluated; they, also, underwent bilateral joint ultrasound of hands and wrists and nail capillaroscopy. The Chi square test and the Fisher’s exact test were used to evaluate the association between binary variables, while the Spearman’s test to evaluate the correlation of continuous ones. A multiple or logistic regression model was calculated in order to define the association between the capillaroscopic alterations and other detected variables.

Results: Articular pain emerged as significantly more frequent in AS (p = 0.0269). No statistically significant differences are detected regarding immunological pattern. ANA and ENA screening resulted positive in 10% in AS and in 5% in CS. No IgA ACPA were detected in AS or CS, while IgG ACPA were positive only in one AS subject. No significant differences were detected between IgM and IgG RFin the two groups (AS 5% and CS 0%). Three fold higher IgG FR in AS compared to CS were detected. ESR levels were significantly higher than CS (p = 0.0405), as well as increased power doppler (PWD) articular uptake (AS 30% vs CS 5% p = 0.081). The capillaroscopic evaluation showed a significant difference in almost each parameter that has been evaluated (logistic regression: number of enlargement p = 0.004; hemorragies p = 0.01 and capillaries p = 0.001), showing a moderate-severe microangiopathy in AS. Interestingly, analyzing only the acromegaly cohort, we noticed higher GH levels at the enrollment in patients which developed capillary enlargements (GH: 0.55 ng/ml IQ 0,6-1,6) compared to other ones (GH: 0.55 ng/ml IQ 0.4-0.7; p = 0.08) and a significant lower number of hemorrhages (p = 0.02) in patients treated with GH antagonist pegvisomant.

Conclusion: Our results demonstrated that joint damage in acromegaly does not seem to have an autoimmune etiology. Therefore, articular damage is mechanical and increased ESR and PWD alterations seems to confirm the presence of an inflammatory component. In addition, acromegaly is characterized by a microvascular pattern of moderate-severe microangiopathy, without correlation to IGF-I, but GH levels. Although requiring further confirmatory studies, our preliminary results seem to indicate how the capillaroscopic examination could be useful to detect earlier microangiopathy and to identify patients with a greater risk of macroangiopathy development.

References:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2020-eular.3134

BEHÇET SYNDROME AND CENTRAL NERVOUS SYSTEM INVOLVEMENT: A DESCRIPTIVE STUDY IN A COHORT OF PATIENTS IN OUR RHEUMATOLOGY DEPARTMENT

N. Plaza Aulestia1, M. J. Pérez1, S. Rodríguez Montero1, J. L. Marenco1,1 Hospital Universitario de Valme, Rheumatology, Seville, Spain

Background: Behçet’s disease (BD) is a variable vessel vasculitis characterized by mucocutaneous lesions (oral and genital ulcers). In addition, it can affect other systems such as vascular, ophthalmological, gastrointestinal tract or central nervous system (CNS). The latter being one of the most serious manifestations of Behçet’s disease. We present a descriptive observational study of a cohort of patients diagnosed with Behçet’s disease with CNS involvement.

Objectives: Our objective is to describe the prevalence and characteristics of various clinical manifestations in patients with Behçet.

Methods: Observational, descriptive, cross-sectional, retrospective design performed in patients with Behçet’s disease in follow-up by the Rheumatology department of the Hospital de Valme, until October 2019. The following information is collected from medical records; sex, mean age at diagnosis, clinical characteristics, HLA B51 positivity and treatment.

Results: Thirty-three patients were diagnosed with Behçet’s disease, with a mean age at diagnosis of 36.22 +/- 10.94 years, female predominance 19 (57.57%). Regarding the determination of HLA B 51; 5 (15.15%) positive, 6 (18.18%) negative and 22 (66.66%) not determined. The following information about clinical manifestations is collected:

We identified 9 patients with CNS involvement; 5 demyelinating lesions (55%), 2 strokes (22%), 1 epilepsy/seizure (11%) and 1 case of CNS vasculitis (11%). Fifty-five percent of the patients were female (55%). Two patients were positive for HLA B51 (22%) and the rest had not been determined. Regarding treatment, all patients received both, oral and intravenous, corticosteroids (57.57%). Regarding treatment, all patients received both, oral and intravenous, corticosteroids (57.57%). Regarding treatment, all patients received both, oral and intravenous, corticosteroids (57.57%). Regarding treatment, all patients received both, oral and intravenous, corticosteroids (57.57%). Regarding treatment, all patients received both, oral and intravenous, corticosteroids (57.57%). Regarding treatment, all patients received both, oral and intravenous, corticosteroids (57.57%). Regarding treatment, all patients received both, oral and intravenous, corticosteroids (57.57%). Regarding treatment, all patients received both, oral and intravenous, corticosteroids (57.57%). Regarding treatment, all patients received both, oral and intravenous, corticosteroids (57.57%).

Disclosure of Interests: NAHIA PLAZA AULESTIA: None declared, MARÍA JOSÉ PÉREZ: None declared, Sergio Rodríguez Montero: None declared, Jose Luis Marenco Speakers bureau: Abbvie, Pfizer, Lilly

DOI: 10.1136/annrheumdis-2020-eular.3281